Prime Medicine PRME Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's common stock, shares authorized (in shares)?
- Prime Medicine (PRME) reported common stock, shares authorized (in shares) of $775M in Q1 2026.
- How has Prime Medicine's common stock, shares authorized (in shares) changed year-over-year?
- Prime Medicine's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $775M to $775M.
- What is the long-term trend for Prime Medicine's common stock, shares authorized (in shares)?
- Over 4 years (2021 to 2025), Prime Medicine's common stock, shares authorized (in shares) has grown at a 27.5% compound annual growth rate (CAGR), from $293.26M to $775M.